Skip to main content
OpenTrials

Clinical trial condition

Refractory Cancer

Explore clinical trials studying Refractory Cancer. Study availability and eligibility vary by location and protocol.

40 public trials 19 recruiting studies
Refine in advanced search Browse all conditions

Refractory Cancer trial results

Recruiting

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589

Conditions
B-cell Lymphoma, B-cell Malignancy, Disease Attributes, +15 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • University of Southern California Norris Comprehensive Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 50 locations
View Trial Details
Recruiting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT05859074

Conditions
Adenocarcinoma, Adenocarcinoma, Sebaceous, Adnexal Carcinoma, +58 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

NCT05852717

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
  • Karmanos Cancer Center (Wayne State University) Detroit, Michigan, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
  • University of Virginia Health System Charlottesville, Virginia, United States
View Trial Details
Recruiting

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

NCT05958121

Conditions
Cancer, Disease Attributes, Neoplasms, +6 more
Locations
  • Universitaetsklinikum Heidelberg AöR Heidelberg, Baden-Wurttemberg, Germany
  • Thoraxklinik Heidelberg gGmbH Heidelberg, Baden-Wurttemberg, Germany
  • Universitaetsklinikum Mannheim GmbH Mannheim, Baden-Wurttemberg, Germany
  • Universitaetsklinikum Tuebingen AöR Tübingen, Baden-Wurttemberg, Germany
View all 29 locations
View Trial Details
Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT03686124

Conditions
Adnexal Diseases, Cancer, Disease Attributes, +35 more
Locations
  • Stanford Cancer Institute Stanford, California, United States
  • University of Colorado, Anschutz Medical Campus Aurora, Colorado, United States
  • University of Miami Hospital and Clinics Miami, Florida, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
View all 21 locations
View Trial Details
Recruiting

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

NCT04421560

Conditions
Disease Attributes, Neoplasms, Pathologic Processes, +6 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Columbia University Medical Center New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details

Related conditions